Estimation of Eroton Product Efficiency in the Therapy of Men with Erectile Dysfunction and Type 2 Diabetes


Ю. М. Гурженко


The clinical efficacy of the drug Eroton in the treatment of erectile dysfunction in 60 patients with diabetes mellitus (DM) was studied. Performance monitoring was carried out using questionnaires on the ICEF scale and Dopplerography. The effectiveness of the use of the drug Eroton in patients with ED and diabetes at a dose of 50 mg was 26.7 %, and those who took Eroton in a dose of 100 mg – 63.3 %, therefore, if the patient has ED and diabetes, it is necessary to prescribe the drug Eroton in a dose of 100 mg initially. When comparing the effectiveness of Eroton with the original drug, it was shown that when using it at a dose of 50 mg, the effectiveness was 31.5 %, and when using it at a dose of 100 mg – 68.5 %. As can be seen from the above, the clinical effectiveness of the drug Eroton is not significantly inferior to the comparison drug.


How to Cite
Гурженко, Ю. М. (2020). Estimation of Eroton Product Efficiency in the Therapy of Men with Erectile Dysfunction and Type 2 Diabetes. Health of Man, (2), 64–70.
Sexology and andrology
Author Biography

Ю. М. Гурженко, Ukrainian Institute of Sexology and Andrology

Yurii M. Gurzhenko


De Berardis G., Franciosi M., Belfiglio M. et al. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked // Diabetes Care. – 2002. – Vol. 25. – Р. 84–91.

Yamaguchi Y., Kumamoto Y. Etiological analysis of male diabetic erectile dysfunction with particular emphasis on findings of vascular and neurological examinations // Nippon Hinyokika Gakkai Zasshi. – 1994. – Vol. 85. – P. 1474–1483.

Лучицкий В.Е. Лікування еректильної дисфункції у чоловіків, хворих на цукровий діабет 2-го типу «Международный эндокринологический журнал», 2015 ISSN 2224-0721 № 8 (72).

Corona J., Mannucci E., Petrone L. et al. NCEP-ATPIII — defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction // J. Sex. Med. – 2007. – Vol. 4. – P. 1038–1045.

The Real-Life Safety and Efficacy of Varenafil (REALISE) – Subgroup analysis of patients with cardiovascular diseases, diabetes mellitus or hypertension // J. Sex. Med. – 2006. – Vol. 3 (Suppl. 3). – P. 25.

Возіанов О.Ф., Горпинченко І.І. Досвід застосування віагри в Україні // Сексология и андрология. – К., 2000, Вып. 5. – С. 3–5.

Горпинченко И.И. Эректильная дисфункция: диагностика и современные методы лечения // Здоровье мужчины. – 2002. – № 1. – С. 9–11.

Горпинченко И.И., Мирошников Я.О. Эректильная дисфункция. – Л., «Медицина світу».

Бюва Ж. Лечение силденафилом, четырёхлетний опыт // Здоровье мужчины. – 2002. – № 2. – С. 11–13.

Горпинченко И.И. Геронтологическая сексопатология: Производственное издание. – Здоровья, 1991. – 168 с.

Rosen R.C., Riley A., Wagner G. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction // Urology. – 1997. – V. 49. – P. 822–830.

Калинченко С.Ю. и соавт. Лечение цитратом силденафила (ВИАГРА) у пациентов с сахарным диабетом // Терапевтический архив. – 1999; 71 (10): 78–80;